scispace - formally typeset
Open AccessJournal Article

Moderate-intensity interval training increases serum brain-derived neurotrophic factor level and decreases inflammation in Parkinson's disease patients.

Reads0
Chats0
TLDR
It is concluded that the improvement of health status of the Parkinson's disease patients after training could be related to the increase of serum BDNF level caused by the attenuated inflammation in those patients.
Abstract
It has been demonstrated that physical training increases serum brain-derived neurotrophic factor (BDNF) in healthy people. The aim of this study was to establish the effect of physical training on the basal serum level of the BDNF in the Parkinson's disease patients (PD patients) in relation to their health status. Twelve PD patients (mean ± S.E.M: age 70 ± 3 years; body mass 70 ± 2 kg; height 163 ± 3 cm) performed a moderate-intensity interval training (three 1-hour training sessions weekly), lasting 8 weeks. Basal serum BDNF in the PD patients before training amounted to 10,977 ± 756 pg x mL(-1) and after 8 weeks of training it has increased to 14,206 ± 1256 pg x mL(-1) (i.e. by 34%, P=0.03). This was accompanied by an attenuation of total Unified Parkinson's Disease Rating Scale (UPDRS) (P=0.01). The training resulted also in a decrease of basal serum soluble vascular cell adhesion molecule 1 (sVCAM-1) (P=0.001) and serum tumor necrosis factor-α (TNF-α) (P=0.03) levels. We have concluded that the improvement of health status of the Parkinson's disease patients after training could be related to the increase of serum BDNF level caused by the attenuated inflammation in those patients.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

BDNF as a Promising Therapeutic Agent in Parkinson's Disease.

TL;DR: Evidence is focused on the evidence that increasing BDNF level due to gene modulation or physical exercise has a neuroprotective effect and could be considered as adjunctive therapy in PD.
Journal ArticleDOI

Aerobic Exercise: Evidence for a Direct Brain Effect to Slow Parkinson Disease Progression

TL;DR: To objectively assess the evidence for a PD exercise benefit, a comprehensive PubMed literature search was conducted, with an unbiased focus on exercise influences on parkinsonism, cognition, brain structure, and brain function.
Journal ArticleDOI

Physical activity and exercise attenuate neuroinflammation in neurological diseases.

TL;DR: Current evidence supporting the disease-altering potential of PA and exercise through modifications of neuroimmune responses, specifically in MDD, SCH, AD and PD is highlighted.
Journal ArticleDOI

The best medicine? The influence of physical activity and inactivity on Parkinson's disease

TL;DR: Physical activity and exercise as a means of attenuating inflammation have led to increased interest in related potential therapeutic targets for PD, and these findings may translate into low‐cost, universally available therapies for PD disease modification or prevention.
References
More filters
Journal ArticleDOI

Age-predicted maximal heart rate revisited.

TL;DR: The findings suggest that the currently used equation for predicting maximal heart rate in older adults underestimates HRmax, which would have the effect of underestimating the true level of physical stress imposed during exercise testing and the appropriate intensity of prescribed exercise programs.
Journal ArticleDOI

Running enhances neurogenesis, learning, and long-term potentiation in mice

TL;DR: The results indicate that physical activity can regulate hippocampal neurogenesis, synaptic plasticity, and learning.
Journal ArticleDOI

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

TL;DR: Overall, available data support the importance of non-cell-autonomous pathological mechanisms in Parkinson's disease, which are mostly mediated by activated glial and peripheral immune cells.
Journal ArticleDOI

Evidence for prescribing exercise as therapy in chronic disease.

TL;DR: The evidence for prescribing exercise therapy in the treatment of metabolic syndrome‐related disorders (insulin resistance, type 2 diabetes, dyslipidemia, hypertension, obesity), heart and pulmonary diseases, muscle, bone and joint diseases, and cancer, depression, asthma and type 1 diabetes is presented.
Related Papers (5)